MedTrace Logo

Study on Combined Use of Letrozole, Mifepristone and Misoprostol in Termination of Pregnancy

NCT01475318 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-11-21

No results posted yet for this study

Summary

By using the combination of mifepristone (anti-progestin), misoprostol (progstanglandin which stimulates uterine contraction), and letrozole (aromatise inhibitor which reduces estrogen production), the abortion process will be more effective.

Conditions

  • Complete Abortion

Interventions

DRUG

mifepristone

200 mg mifepristone on day 1

DRUG

Letrozole

Letrozole 10mg PO on day 1, day 2, and day 3

DRUG

Misoprostol

misoprostol 800mcg PV on day 3

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01475318 on ClinicalTrials.gov